FDA Patient Affairs Office Needed To Improve Conflict Of Interest, NORD Says
Executive Summary
Elevating FDA's handling of patient-related issues could help ensure more patients get on advisory committees, rare disease advocates say, but agency notes that waivers are always an option.
You may also be interested in...
FDA Safety Meetings: Outpatient Drugs, Hypoglycemia Getting Limelight
US agency's events could address a touchy subject: how much responsibility does FDA have for preventing adverse events, and how much falls to physicians?
Rare Diseases: CBER Looks To ‘Lean Into’ Accelerated Approval, Align More With CDER
US FDA biologics center officials spoke about their efforts to increase collaboration and harmonization with the drugs center, and to internally involve more review disciplines in evaluating biomarker evidence, during a Reagan-Udall Foundation meeting that weighed potential use of accelerated approval for neuronopathic mucopolysaccharidoses disorders.
RWE: Non-Interventional Studies Must Be Able To Distinguish A True Treatment Effect, US FDA Says
Agency describes a host of issues sponsors should consider and address before pursuing observational or case-control studies to support regulatory decision-making on drug efficacy or safety; new draft guidance was issued under the FDA’s Real-World Evidence program.